rivaroxaban clonmel 15 mg film-coated tablets rivaroxaban clonmel 20 mg film-coated tablets
clonmel healthcare ltd - rivaroxaban; rivaroxaban - film-coated tablet - rivaroxaban
rivaroxaban clonmel 15 mg hard capsules rivaroxaban clonmel 20 mg hard capsules
clonmel healthcare ltd - rivaroxaban; rivaroxaban - capsule, hard - rivaroxaban
rivaroxaban pharos 15mg / rivaroxaban pharos 20mg film-coated tablets
pharos – pharmaceutical oriented services limited lesvou str. (end), thesi loggos, industrial zone, 144 52 metamorfossi attikis,, greece - rivaroxaban - film-coated tablet - rivaroxaban 15 mg rivaroxaban 20 mg - antithrombotic agents
rivaroxaban viatris (previously rivaroxaban mylan)
mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antithrombotic agents - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers. rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.-------adults prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
rivaroxaban medichem 2.5mg film-coated tablets
medichem, s.a. fructuós gelabert 6-8, 08970, sant joan despí, (barcellona), spain - rivaroxaban - film-coated tablet - rivaroxaban 2.5 mg - antithrombotic agents
rivaroxaban medichem 10mg film-coated tablets
medichem, s.a. fructuós gelabert 6-8, 08970, sant joan despí, (barcellona), spain - rivaroxaban - film-coated tablet - rivaroxaban 10 mg - antithrombotic agents
rivaroxaban medichem 15mg film-coated tablets
medichem, s.a. fructuós gelabert 6-8, 08970, sant joan despí, (barcellona), spain - rivaroxaban - film-coated tablet - rivaroxaban 15 mg - antithrombotic agents
rivaroxaban medichem 20mg film-coated tablets
medichem, s.a. fructuós gelabert 6-8, 08970, sant joan despí, (barcellona), spain - rivaroxaban - film-coated tablet - rivaroxaban 20 mg - antithrombotic agents
reddy-rivaroxaban tablet
dr reddy's laboratories ltd - rivaroxaban - tablet - 2.5mg - rivaroxaban 2.5mg
apo-rivaroxaban tablet
apotex inc - rivaroxaban - tablet - 2.5mg - rivaroxaban 2.5mg